Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Yun Yen, Samuel So, Michal Rose, M. Wasif Saif, Edward Chu, Shwu Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung Chi Cheng

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

Original languageEnglish (US)
Pages (from-to)4083-4092
Number of pages10
JournalAnticancer Research
Volume29
Issue number10
StatePublished - Oct 2009
Externally publishedYes

Keywords

  • Adjuvant therapy
  • Capecitabine
  • Hepatocellular carcinoma (HCC)
  • Phase I/II
  • PHY906

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this